Home/Pipeline/Tralokinumab (Lifecycle Management)

Tralokinumab (Lifecycle Management)

Atopic Dermatitis

Approved/CommercialActive

Key Facts

Indication

Atopic Dermatitis

Phase

Approved/Commercial

Status

Active

Company

Leo Pharma

About Leo Pharma

LEO Pharma is a long-established, private Danish pharmaceutical company with a singular focus on medical dermatology. The company is in a strong commercial phase, reporting a third consecutive year of double-digit revenue growth in 2025, a return to profitability, and positive free cash flow. Its strategy centers on advancing its pipeline in underserved dermatological areas, supporting external research through its Investigator Initiated Studies program, and building alliances to shape the future of skin disease treatment.

View full company profile

Therapeutic Areas

Dermatology

Other Atopic Dermatitis Drugs

Drug	Company	Phase	Status
PEP Biologic™	Intent Biologics	Unknown	Active
HBM7575 (SKB575)	Harbour BioMed	IND Filed	Active (Global)
ITK inhibitor	Acellera	Pre-clinical	Hit-to-Lead
Encube-003	Encube Ethicals	Preclinical	Active
ENS-002 (Fermata Derm)	Concerto Biosciences	Pre-clinical	Active
Lead Program	MatriSys Bioscience	Phase 1	Active
Atopic Dermatitis Trial	Well Pharma Medical Research	Not Specified	Active
MEndoB	Micreos	Pre-clinical	Active
Atopic Dermatitis Program	Lxbio Pharmaceuticals	Pre-clinical	Active
B244	AOBiome	Phase 3	Active
CTO1681	CytoAgents	Pre-clinical	Active
DS107	DS Biopharma	Phase 2	Active